AI assistant
Sending…
Phathom Pharmaceuticals, Inc. — Director's Dealing 2023
Apr 7, 2023
32407_dirs_2023-04-07_2056b19f-ce9f-426d-bfaa-0b3e6d19e12b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2023-04-06
Reporting Person: Henderson Molly (CFO and CBO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-04-06 | Common Stock | S | 3439 | $7.27 | Disposed | 72576 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 338.86 | Indirect |
Footnotes
F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2022.
F2: Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.
More from Phathom Pharmaceuticals, Inc.
Regulatory Filings
2026
May 21
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Annual Report
2026
Apr 7
Proxy Solicitation & Information Statement
2026
Apr 7
Regulatory Filings
2026
Mar 27
Director's Dealing
2026
Mar 3
Annual Report
2026
Feb 26
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 12